All In Biotech

Drug Trial Radar · NCT01313221

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Mar 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

310

Actual

Start

Apr 2011

Primary completion

Dec 2012

Study completion May 2013

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • etanerceptBiological

    Administered by subcutaneous injection

  • Topical agentsDrug

    Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following: * hydrocortisone 2.5% * betamethasone valerate 0.1% * betamethasone dipropionate 0.05% * clobetasol 0.05% * calcitriol * calcipotriol plus betamethsone dipropionate 0.05%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24Time frame: Week 12 and Week 24

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Surrey, British Columbia, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Winnipeg, Manitoba, Canada

  • Research Site

    Moncton, New Brunswick, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Courtice, Ontario, Canada

  • Research Site

    Greater Sudbury, Ontario, Canada

  • Research Site

    Markham, Ontario, Canada

  • Research Site

    Mississauga, Ontario, Canada

  • Research Site

    North Bay, Ontario, Canada

  • Research Site

    Peterborough, Ontario, Canada

  • Research Site

    Richmond Hill, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Waterloo, Ontario, Canada

  • Research Site

    Windsor, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Saint-Hyacinthe, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.